Authors' recommendations: Ovarian cancer is the sixth most common cancer for women in the UK. Symptoms of ovarian cancer are often vague early on, and many women are not diagnosed until after the cancer has grown and spread to other parts of the body. Less than half of women with ovarian cancer survive five years from diagnosis, with many becoming resistant to current treatments. Pelareorep is a living virus that may kill cancer cells but not affect healthy cells. It is delivered directly into the bloodstream along with paclitaxel (a chemotherapy drug that's already used to treat ovarian cancer). Pelareorep is currently being studied to see how well it works, and whether it is safe to use. If pelareorep is licensed for use in the UK, it will provide a new treatment option for women with ovarian, fallopian tube or peritoneal cancer that has returned despite already having received chemotherapy at least once before.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/pelareorep-in-combination-with-paclitaxel-for-recurrent-or-persistent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)